Sir,
We would like to thank Oliver et al (2013) for bringing to our attention these data issues. After careful checking, it is clear that the main source of discrepancy is the difference between the numbers of cancer registrations for [2004] [2005] [2006] [2007] , as available in 2010, and the updated numbers released in 2011. Whereas we were aware that there can be substantial delays in registration of some cancers, we had assumed that any changes made after the data are first published would be trivial at a population level and would not affect the analysis of trends over time. Unfortunately, we were wrong. Our projections for leukemia, in particular, are likely to have substantially underestimated the future burden of the disease.
Consider the numbers of all cancers (excluding non-melanoma skin cancer) in 2004 in England; according to the MB1 no. 35 (released: 19 December 2006) , there were 233 621 cancer cases, but updated statistics released in 2011 recorded 241 700 cases -an increase of 3.3%. The change is particularly great for leukemia (ICD-10: C91-C95; 10.5%) and myeloma (C90; 8.8%). In Table 1 , we show how the age-standardised rates of leukemia for each year between 2005 and 2009 has increased in successive data releases. The increase in rates as the data matures will severely distort recent trends and will attenuate projections downwards. Years of data used 1975-2007 1984-2009 1975-2005 1975-2007 1975-2009 Non-Hodgkin lymphoma Statistical methods for predicting the eventual number of registrations for each of the last few years deserve a separate investigation, but any approach will need to take into account the changing methodology used in cancer registration, as that will have lead to more timely registration of many tumours. We urge the Office for National Statistics to consider publishing estimated 'complete registration' data using, for instance, the method adopted by the Surveillance, Epidemiology and End Results (Midthune et al, 2005) , who published both unadjusted and delay-adjusted rates (National Cancer Institute, 2012). Here we simply note that the issue is present for virtually all cancer sites to a greater or lesser extent, but appears to be independent of sex and age for any given site (Table 2) .
We have analysed the most recently released data and made projections to 2030 using all data up to 2009, and also limited the analysis to data between 1975 and 2005. The resulting fits for leukemia are shown in Figure 1 , together with our previously published results based on the data from the 2010 release for . It is seen that the old data yield particularly optimistic projections, but by including the most recent 4 years of the new data the projections are more optimistic than when these data are excluded. We have also projected all cancers (excluding non-melanoma skin cancer) other than prostate cancer in men and all cancers other than breast cancer in women, treating them as a single site. The reason for the exclusion of prostate and breast cancer is that their incidence has been hugely affected by PSA testing and screening mammography so that the age-period cohort model does not provide a reasonable fit. Table 3 summarises the effect of using different data sets on agestandardised projections for 2030 for leukaemia, non-Hodgkin lymphoma, myeloma, and for all non-prostate male cancers and non-breast female cancers. The increase in projected rates for 2030, although not quite as great as obtained by Oliver et al (2013) , is substantial (about 11% for non-Hodgkin lymphoma and 20-25% for leukemia and myeloma). The projected rates for all nonprostate and non-breast cancers for 2030 are about 9% greater using the new data than they are using the old data (in both cases for .
In summary, late registrations, particularly of haematological cancers, have a profound effect on observed trends in cancer incidence and should be taken into account when projecting future rates.
